Renal transplant immunology in the last 20 years: A revolution towards graft and patient survival improvement

References

• Starzl T. The mystique of organ transplantation. J Am Coll Surg 2005 Aug;201(2):160–170.
   PubMed Web of Science ®Google Scholar
• Spreafico R, Mitchell S, Hoffmann A. Training the 21st century immunologist. Trends Immunol 2015 May;36(5):283–285.
   PubMed Web of Science ®Google Scholar
• Medawar P. The immunology of transplantation. Harvey Lectures. 1956;(52):144--176.
   Google Scholar
• Owen JA, Punt J, Stranford S. The Major Histocompatibility Complex and Antigen Presentation. Kuby Immunology, Ch. 8, Lauren Schultz, Ed. 2013; pp. 262--284. W.H. Freeman, New York.
   Google Scholar
• Medawar P. The behavior and fate of skin autografts and skin homografts in rabbits. J Anat 1944;78:176–199.
   PubMedGoogle Scholar
• Barker C, Markmann JF. Historical overview of transplantation. Med CSHP, editors, LA Turka and KJ Wood.; 2013, Cold Spring Harbor Laboratory Press, Long Island, New York, USA.
   Google Scholar
• Snell G. Histocompatibility genes of the mouse. I. Demonstration of weak histocompatibility differences by immunization and controlled tumor dosage. J Natl Cancer Inst 1958 Apr;20(4):787–824.
   PubMedGoogle Scholar
• Snell G. Methods for the study of histocompatibility genes. J Genet 1948;49:87–108.
   PubMed Web of Science ®Google Scholar
• Murray J, Merril J, Harrison J. Renal homotransplantations in identical twins. Surg Forum 1955;6:432–436.
   PubMedGoogle Scholar
• Dausset J.Isoleuco-anticorps. Acta Haematol 1958; 20:156–166.
   PubMedGoogle Scholar
• Robinson J, Halliwell J, Hayhurst J, et al. The IPD and IMGT/HLA database: allele variant databases. 2015; Oxford University Press, Oxford, UK.
   Google Scholar
• Benacerraf B, McDevitt H. Histocompatibility-linked immune response genes. Science 1972 Jan; 175(4019):273–279.
   PubMed Web of Science ®Google Scholar
• Zinkernagel R, Doherty P. Restriction of in vitro T cell-mediated cytotoxicity in lymphocytic choriomeningitis within a syngeneic or semiallogeneic system. Nature 1974 Apr;19(248):701–702.
   Google Scholar
• Bjorkman P, Sape MSB, Bennet W, et al. Structure of the human class I histocompatibility antigen, HLA-A2. Nature 1987 Oct;8–14(329):506–512.
   Google Scholar
• Murphy K. In: Janeway's immmnobiology, 9th ed. Ch. 15, Autoimmunity and transplantation, pp. 683--695. Ed., D Schanck. Garland Science, Taylor and Francis, New York; 2016.
   Google Scholar
• Brown J, Jardetzky T, Gorga J, et al. Three-dimensional structure of the human class II histocompatibility antigen HLA-DR1. Nature 1993 Jul;364(6432):33–39.
   PubMed Web of Science ®Google Scholar
• Shin M, Kim S. Incompatible kidney transplantation—current status and uncertainties. J Transplant 2011;2(11):4–21.
   Google Scholar
• Tanabe T, Ishida H, Horita S, et al. Decrease of blood type antigenicity over the long-term after ABO-incompatible kidney transplantation. Transpl Immunol 2011 Jul;25(1):1–6.
   PubMed Web of Science ®Google Scholar
• Ishida H, Tanabe K, Toma H, Akiba T. Therapeutic apheresis therapy for ABO-incompatible renal transplantations. Ther Apher Dial 2003 Dec;7(6):520–528.
   PubMed Web of Science ®Google Scholar
• Rydberg L, Breimer M, Brynger H, Samuelsson B. ABO-incompatible kidney transplantation (A2 to O). Qualitative and semiquantitative studies of the humoral immune response against different blood group A antigens. Transplantation 1990 May;49(5):954–960.
   PubMed Web of Science ®Google Scholar
• Opelz G. HLA matching and cadaver kidney transplantation-status 1984. Ulster Med J 1985 Aug; 54(Suppl):70–75.
   Google Scholar
• Takemoto S, Terasaki P, Cecka J, et al. Survival of nationally shared, HLA-matched kidney transplants from cadaveric donors – the UNOS Scientific Renal Transplant Registry. N Engl J Med 1992 Sep;327(12):834–839.
   PubMed Web of Science ®Google Scholar
• Gabel H, Persson U, Moller E. The significance of repeated HLA-A, -B, and -DR mismatches in renal transplantation. Transplant Proc 1990 Feb;22(1):145–146.
   PubMed Web of Science ®Google Scholar
• Zhou Y, Cecka J. Effect of HLA matching on renal transplant survival. Clin Transpl 1993:499–510. PubMed PMID: 7918184.
   PubMedGoogle Scholar
• Yussim A, Efter T, Shmueli D, Shapira Z. The impact of repeated DR mismatching and preformed antibodies on human kidney retransplantation.Transplant Proc 1987 Oct;19(5):3653–3654.
   PubMed Web of Science ®Google Scholar
• Matsushita K, Sakamoto K, Sakamaki T, et al. Microchimerism in renal transplant recipients correlates with better HLA-DRB1-matched status. Transplant Proc 1997 Jun;29(4):2290–2293.
   PubMed Web of Science ®Google Scholar
• Thompson J, Thacker LR 2nd, Krishnan G. Human leukocyte antigens DR and AB and kidney retransplantation. Transplantation 2003 Mar 15;75(5):718–723.
   PubMed Web of Science ®Google Scholar
• Su X, Zenios SA, Chakkera H, Milford EL, Chertow GM. Diminishing significance of HLA matching in kidney transplantation. Am J Transplant 2004 Sep;4(9):1501–1508.
   PubMed Web of Science ®Google Scholar
• Hiesse C, Pessione F, Houssin D. The case to abandon human leukocyte antigen matching for kidney allocation: would it be wise to throw out the baby with the bathwater? Transplantation 2004 Feb;77(4):623–626.
   PubMed Web of Science ®Google Scholar
• Wissing K, Fomegné G, Broeders N, et al. HLA mismatches remain risk factors for acute kidney allograft rejection in patients receiving quadruple immunosuppression with anti-interleukin-2 receptor antibodies. Transplantation 2008 Feb;85(3):411–416.
   PubMed Web of Science ®Google Scholar
• Foster B, Dahhou M, Zhang X, et al. Impact of HLA mismatch at first kidney transplant on lifetime with graft function in young recipients. Am J Transplant 2014 Apr;14(4):876–885.
   PubMed Web of Science ®Google Scholar
• Danovitch GCJ. Allocation of deceased donor kidneys: past, present, and future. Am J Kidney Dis 2003 Nov;42(5):882–890.
   PubMed Web of Science ®Google Scholar
• Broeders N, Racapé J, Hamade A, et al. A new HLA allocation procedure of kidneys from deceased donors in the current era of immunosuppression. Transplant Proc 2015 Mar;47(2):267–274.
   PubMed Web of Science ®Google Scholar
• Mehra N, Siddiqui J, Baranwal A, et al. Clinical relevance of antibody development in renal transplantation. Ann NY Acad Sci 2013 Apr;1283:30–42.
   PubMed Web of Science ®Google Scholar
• Opelz G, Wujciak T, Döhler B, et al. HLA compatibility and organ transplant survival. Rev Immunogenet 1999;1(3):334–342.
   PubMedGoogle Scholar
• Opelz G, Döhler B. Influence of immunosuppressive regimens on graft survival and secondary outcomes after kidney transplantation. Transplantation 2009 Mar;87(6):795–802.
   PubMed Web of Science ®Google Scholar
• Opelz G, Döhler B. Effect of human leukocyte antigen compatibility on kidney graft survival: comparative analysis of two decades. Transplantation 2007 Jul;84(2):137–143.
   PubMed Web of Science ®Google Scholar
• Súsal C, Opelz G. Current role of human leukocyte antigen matching in kidney transplantation. Curr Opin Organ Transplant 2013 Aug;18(4):438–444.
   PubMed Web of Science ®Google Scholar
• Dierselhuis M, Goulmy E. The relevance of minor histocompatibility antigens in solid organ transplantation. Curr Opin Organ Transplant 2009 Aug;14(4):419–425.
   PubMed Web of Science ®Google Scholar
• Perreault C, Décary F, Brochu S, et al. Minor histocompatibility antigens. Blood 1990 Oct;76(7):1269–1280.
   PubMed Web of Science ®Google Scholar
• Hankey K, Drachenberg C, Papadimitriou J, et al. MIC expression in renal and pancreatic allografts. Transplantation 2002;73:304–306.
   PubMed Web of Science ®Google Scholar
• Zou Y, Stastny P, Süsal C, et al. Antibodies against MICA antigens and kidney transplant rejection. N Engl J Med 2007 Sep;357(13):1293–1300.
   PubMed Web of Science ®Google Scholar
• Lei L, Zhengyu LWW, Guangheng L, et al. Role of MICA antibodies in solid organ transplantation. 2014;28(10):152–160.
   Google Scholar
• Nankivell B, Alexander S. Rejection of the kidney allograft. N Engl J Med. 2010 Oct;363(15):1451–1462.
   PubMed Web of Science ®Google Scholar
• Halloran P, Reeve J, Pereira A, et al. Antibody-mediated rejection, T cell-mediated rejection, and the injury-repair response: new insights from the Genome Canada studies of kidney transplant biopsies. Kidney Int 2014 Feb;85(2):258–264.
   PubMed Web of Science ®Google Scholar
• Chinen J, Buckley R. Transplantation immunology: solid organ and bone marrow. J Allergy Clin Immunol. 2010 Feb;125(2):S324–S335.
   PubMed Web of Science ®Google Scholar
• Sicard A, Ducreux S, Rabeyrin M, et al. Detection of C3d-binding donor-specific anti-HLA antibodies at diagnosis of humoral rejection predicts renal graft loss. J Am Soc Nephrol 2015 Feb;26(2):457–467.
   PubMed Web of Science ®Google Scholar
• Gosset C, Lefaucher C, Glotz D. New insights in antibody-mediated rejection. Curr Opin Nephrol Hypertens 2014 Nov;23(6):597–604.
   PubMed Web of Science ®Google Scholar
• Kim M, Martin S, Townsed K, Gabardi S. Antibody-mediated rejection in kidney transplantation: a review of pathophysiology, diagnosis, and treatment options. Pharmacotherapy 2014 Jul;34(7):733–744.
   PubMed Web of Science ®Google Scholar
• Zito A, Schena A, Grandaliano G, et al. Increasing relevance of donor-specific antibodies in antibody-mediated rejection. J Nephrol 2013 Mar–Apr;26(2):237–242.
   PubMed Web of Science ®Google Scholar
• Reyes N. Flashback to 2002: a retesting and reanalysis suggests an important role of DSA. Clin Transpl 2012:257–260. PubMed PMID: 23721030.
   PubMedGoogle Scholar
• Huang Y, Ramon D, Luan F, Sung R, Samaniego M. Incidences of preformed and de novo donor-specific HLA antibodies and their clinico-histological correlates in the early course of kidney transplantation. Clin Transpl 2012:247–256.
   PubMedGoogle Scholar
• Loupy A, Hill G, Jordan S. The impact of donor-specific anti-HLA antibodies on late kidney allograft failure. Nat Rev Nephrol 2012 Apr;8(6):348–357.
   PubMed Web of Science ®Google Scholar
• Gaston R, Cecka J, Kasiske B, et al. Evidence for antibody-mediated injury as a major determinant of late kidney allograft failure. Transplantation 2010;90(1):68–74.
   PubMed Web of Science ®Google Scholar
• Salvadori M, Bertoni E. What's new in clinical solid organ transplantation by 2013. Transplantation 2014;4(4):243–266.
   Google Scholar
• Guttmann R. Renal transplantation (first of two parts). N Engl J Med 1979 Nov 1;301(18):975–982.
   PubMed Web of Science ®Google Scholar
• Denecke C, Tullius S. Innate and adaptive immune responses subsequent to ischemia-reperfusion injury in the kidney. Prog Urol. 2014 Jun;24(Suppl 1):S13–S19.
   PubMed Web of Science ®Google Scholar
• Strom T. Smith lecture: taming T cells. J Am Soc Nephrol 2007 Nov;18(11):2824–2832.
   PubMed Web of Science ®Google Scholar
• Matzinger P. Tolerance, danger, and the extended family. Annu Rev Immunol 1994;12:991–1045.
   PubMed Web of Science ®Google Scholar
• Land W, Schneeberger H, Schleibner S, et al. The beneficial effect of human recombinant superoxide dismutase on acute and chronic rejection events in recipients of cadaveric renal transplants. Transplantation 1994;57:211–217.
   PubMed Web of Science ®Google Scholar
• Land W, Messmer K. The impact of ischemia/reperfusion injury on specific and non-specific, early and late chronic events after organ transplantation. Transplant Rev 1996;10:236–253.
   Google Scholar
• Podestà M, Cucchiari D, Ponticelli C. The diverging roles of dendritic cells in kidney allotransplantation. Transplant Rev 2015 Jul;29(3):114–120.
   Web of Science ®Google Scholar
• LaRosa D, Rahman A, Turka L. The innate immune system in allograft rejection and tolerance. J Immunol 2007 Jun;178(12):7503–7509.
   PubMed Web of Science ®Google Scholar
• Jang H, Ko G, Wasowska B, Rabb H. The interaction between ischemia-reperfusion and immune responses in the kidney. J Mol Med (Berl) 2009 Sep;87(9):859–864.
   PubMed Web of Science ®Google Scholar
• Oberbarnsheidt M, Lakkis F. Innate allorecognition. Immunol Rev 2014 Mar;258(1):145–149.
   PubMed Web of Science ®Google Scholar
• Land W. Chronic allograft dysfunction: a model disorder of innate immunity. Biomed J 2013 Mar;258(1):145–149.
   Google Scholar
• Pekalski M, Jenkinson S, Willet J, et al. Renal allograft rejection: examination of delayed differentiation of Treg and Th17 effector T cells. Imunobiology 2013 Mar;218(3):303–310.
   PubMed Web of Science ®Google Scholar
• Shi X, Que R, Liu B, Li M, Cai J, Shou D, et al. Role of IL-21 signaling pathway in transplant-related biology. Transplant Rev (Orlando). 2016 Jan;30(1):27--30. doi: 10.1016/j.trre.2015.06.003. Epub 2015 Jul 3. Review.
   Google Scholar
• Cavaillé-Coll M, Bala S, Velidedeoglu E, et al. Summary of FDA workshop on ischemia reperfusion injury in kidney transplantation. Am J Transplant 2013 May;13(5):1134–1148.
   PubMed Web of Science ®Google Scholar
• Solez K. History of the Banff classification of allograft pathology as it approaches its 20th year. Curr Opin Org Transplant 2010 Feb;15(1):49–51.
   PubMed Web of Science ®Google Scholar
• Nankivell B, Borrows RJ, Fung CL, O'Connell PJ, Allen RD, Chapman JR. The natural history of chronic allograft nephropathy. N Engl J Med 2003;349(24):2326–2333.
   Google Scholar
• Cosio F, Grande J, Larson T, et al. Kidney allograft fibrosis and atrophy early after living donor transplantation. Am J Transplant 2005;5:1130–1136.
   PubMed Web of Science ®Google Scholar
• Nankivell B, Fenton-Lee C, Kuypers D, et al. Effects of histological damage on long-term kidney transplant outcome. Transplantation 2001;71:515–523.
   PubMed Web of Science ®Google Scholar
• Park W, Griffin M, Cornell L, et al. Fibrosis with inflammation at one year predicts transplant functional decline. J Am Soc Nephrol 2010;21:1987–1997.
   PubMed Web of Science ®Google Scholar
• Naesens M, Kuypers D, De Vusser K, et al. Chronic histological damage in early indication biopsies is an independent risk factor for late renal allograft failure. Am J Transplant 2013 Jan;13(1):86–99.
   PubMed Web of Science ®Google Scholar
• Lobb I, Davisom M, Carter D, et al. Hydrogen sulfide treatment mitigates renal allograft ischemia reperfusion injury during cold storage and improves early transplant kidney function and survival following allogeneic renal transplantation. J Urol 2015 Jul 31;S0022–5347(15):4505–4508.
   Google Scholar
• Ponticelli C. Ischaemia-reperfusion injury: a major protagonist in kidney transplantation. Nephrol Dial Transplant 2014 Jun;29(6):1134–1140.
   PubMed Web of Science ®Google Scholar
• Ysebaert D, De Greef K, De Beuf A, et al. T cells as mediators in renal ischemia/reperfusion injury. Kidney Int 2004 Aug;66(2):491–496.
   PubMed Web of Science ®Google Scholar
• Daniel C, Horvath S, Allen P. A basis for alloreactivity: MHC helical residues broaden peptide recognition by the TCR. 1998;8:543–552.
   Google Scholar
• Gould D, Auchincloss H Jr. Direct and indirect recognition: the role of MHC antigens in graft rejection. Imunol Today 1999 Feb;20(2):77–82. Review.
   Google Scholar
• Rogers N, Lechler R. Allorecognition. Am J Transplant 2001 Jul;1(2):97–102.
   PubMed Web of Science ®Google Scholar
• Duquesnoy R. Epitope-based human leukocyte antigen matching for transplantation. Curr Opin Organ Transplant 2014 Aug;19(4):418–419.
   PubMed Web of Science ®Google Scholar
• Wiebe C, Pochinco D, Blydt-Hansen T, et al. Class II HLA epitope matching-A strategy to minimize de novo donor-specific antibody development and improve outcomes. Am J Transplant 2013 Dec;13(12):3114–3122.
   PubMed Web of Science ®Google Scholar
• Otten H, Joosten I, Allebes W, et al. The PROCARE consortium: toward an improved allocation strategy for kidney allografts. Transpl Immunol 2014 Oct;31(4):184–190.
   PubMed Web of Science ®Google Scholar
• Shrestha BM. Immunology for renal transplantation. J Transplant Technol Res 2014 Apr;4:130.
   Google Scholar
• Heidt S, Segundo DCR, Wood K. The impact of Th17 cells on transplant rejection and the induction of tolerance. Curr Opin Organ Transplant 2010 Aug;15(4):456–461.
   PubMed Web of Science ®Google Scholar
• Askar M. T helper subsets & regulatory T cells: rethinking the paradigm in the clinical context of solid organ transplantation. Int J Immunogenet 2014 Jun;41(3):185–194.
   PubMed Web of Science ®Google Scholar
• Liu Z, Fan H, Jiang S. CD4(+) T-cell subsets in transplantation. Immunol Rev 2013 Mar;252(1):183–191.
   PubMed Web of Science ®Google Scholar
• Lee Y, Mukasa R, Hatton R, Weaver C. Developmental plasticity of Th17 and Treg cells. Curr Opin Immunol 2009 Jun;21(3):274–280.
   PubMed Web of Science ®Google Scholar
• Itoh M, Takahashi T, Skaguchi N, et al. Thymus and autoimmunity: production of CD25+CD4+ naturally anergic and suppressive T cells as a key function of the thymus in maintaining immunologic self-tolerance. J Immunol 1999;162:5317–5326.
   PubMed Web of Science ®Google Scholar
• Kang S, Tang O, Bluestone J. CD4+CD25+ regulatory T cells in transplantation: progress, challenges and prospects. Am J Transplant 2007 Jun;7(6):1457–1463.
   PubMed Web of Science ®Google Scholar
• Wood K, Bushell A, Hester J. Regulatory immune cells in transplantation. Nat Rev Immunol 2012 May 25;12(6):417–430.
   PubMed Web of Science ®Google Scholar
• Juvet S, Whatcott A, Bushell A, Wood K. Harnessing regulatory T cells for clinical use in transplantation: the end of the beginning. Am J Transplant 2014 Apr;14(4):750–763.
   PubMed Web of Science ®Google Scholar
• Valujskikh A, Li X. Frontiers in nephrology: T cell memory as a barrier to transplant tolerance. J Am Soc Nephrol 2007 Aug;18(8):2252–2261.
   PubMed Web of Science ®Google Scholar
• Mengel M, Campbell P, Gebel H, et al. Precision diagnostics in transplantation: from bench to bedside. Am J Transplant 2013 Mar;13(3):562–568.
   PubMed Web of Science ®Google Scholar
• Xu Y, Jin J, Wang H, et al. The regulatory/cytotoxic infiltrating T cells in early renal surveillance biopsies predicts acute rejection and survival. Nephrol Dial Transplant 2012 Jul;27(7):2958–2965.
   PubMed Web of Science ®Google Scholar
• Akoglu B, Lafferton B, Kalb S. Rejection quantity in kidney transplant recipients is associated with increasing intracellular interleukin-2 in CD8+ T-cells. Transpl Immunol 2014 Jun;31(1):17–21.
   PubMed Web of Science ®Google Scholar
• Mason D, Morris P. Inhibition of the accumulation, in rat kidney allografts of specific – but not nonspecific – cytotoxic cells by cyclosporine. Transplantation 1984 Jan;37(1):46–51.
   PubMed Web of Science ®Google Scholar
• Loveland B, Hogarth P, Ceredig R, McKenzie I. Cells mediating graft rejection in the mouse. I. Lyt-1 cells mediate skin graft rejection. J Exp Med 1981 May;153(5):1044–1057.
   PubMed Web of Science ®Google Scholar
• Dallman M, Wood K, Morris P. Specific cytotoxic T cells are found in the nonrejected kidneys of blood-transfused rats. J Exp Med 1987 Feb;165(2):566–571.
   PubMed Web of Science ®Google Scholar
• Taylor A, Negus S, Negus M, et al. Pathways of helper CD4 T cell allorecognition in generating alloantibody and CD8 T cell alloimmunity. Transplantation 2007 Apr;83(7):931–937.
   PubMed Web of Science ®Google Scholar
• Gaughan A, Wang J, Pelletier R, et al. Key role for CD4 T cells during mixed antibody-mediated rejection of renal allografts. Am J Transplant 2014 Feb;14(2):284–294.
   PubMed Web of Science ®Google Scholar
• Chapman T, Keating G. Basiliximab: a review of its use as induction therapy in renal transplantation. Drugs 2003;63(24):2803–2835.
   PubMed Web of Science ®Google Scholar
• Kasiske B, Zeier M, Chapman J, et al. Kidney disease: improving global outcomes. KDIGO clinical practice guideline for the care of kidney transplant recipients: a summary. Kidney Int 2010 Feb;77(4):299–311.
   PubMed Web of Science ®Google Scholar
• Chaplin D. Overview of the immune response. J Allergy Clin Immunol 2010 Feb;125(2 Suppl 2):S3–S23.
   PubMed Web of Science ®Google Scholar
• Mandal A, Viswanathan C. Natural killer cells: in health and disease. Hematol Oncol Stem Cell Ther 2015 Jun;8(2):47–55.
   PubMedGoogle Scholar
• Akiyoshi T, Hirohashi T, Alessandrini A, et al. Role of complement and NK cells in antibody-mediated rejection. Hum Immunol 2012 Dec;73(12):1226–1232.
   Web of Science ®Google Scholar
• Neudoerfl C, Mueller B, Blume C, et al. The peripheral NK cell repertoire after kidney transplantation is modulated by different immunosuppressive drugs. Front Immunol 2013 Feb;28:4–46.
   Google Scholar
• Heidecke C, Araujo J, Kupiec-Weglinski J, et al. Lack of evidence for an active role for natural killer cells in acute rejection of organ allografts. Transplantation 1985 Oct;404(4):441–444.
   Google Scholar
• Suárez-Álvarez B, Fernández-Sánchez A, López-Vázquez A, et al. NKG2D and its ligands: active factors in the outcome of solid organ transplantation? Kidney Int Suppl 2011 Aug;1(2):52–57.
   Web of Science ®Google Scholar
• Colvin R. Antibody-mediated renal allograft rejection: diagnosis and pathogenesis. J Am Soc Nephrol 2007 Apr;18(4):1046–1056.
   PubMed Web of Science ®Google Scholar
• Alvarez-Márquez A, Aguilera I, Gentil M, et al. Donor-specific antibodies against HLA, MICA, and GSTT1 in patients with allograft rejection and C4d deposition in renal biopsies. Transplantation 2009 Jan;87(1):94–99.
   PubMed Web of Science ®Google Scholar
• Djamali A, Kaufman D, Ellis T, et al. Diagnosis and management of antibody-mediated rejection: current status and novel approaches. Am J Transplant 2014 Feb;14(2):255–271.
   PubMed Web of Science ®Google Scholar
• Böhmig G, Exner M, Habicht A, et al. Capillary C4d deposition in kidney allografts: a specific marker of alloantibody-dependent graft injury. J Am Soc Nephrol 2002 Apr;13(4):1091–1099.
   PubMed Web of Science ®Google Scholar
• Kikic Z, Kainz A, Kozakowski N, et al. Capillary C4d and kidney allograft outcome in relation to morphologic lesions suggestive of antibody-mediated rejection. Clin J Am Soc Nephrol 2015 Aug;7(10):1435–1443.
   PubMed Web of Science ®Google Scholar
• Sis B, Mengel M, Haas M, et al. Banff '09 meeting report: antibody-mediated graft deterioration and implementation of Banff working groups. Am J Transplant 2010 Mar;10(3):464–471.
   PubMed Web of Science ®Google Scholar
• Haas M, Sis B, Racusen L, et al. Banff meeting report writing committee. Banff 2013 meeting report: inclusion of c4d-negative antibody-mediated rejection and antibody-associated arterial lesions. Am J Transplant 2014 Feb;14(2):272–283.
   PubMed Web of Science ®Google Scholar
• Veale J, Liang L, Zhang Q, et al. Noninvasive diagnosis of cellular and antibody-mediated rejection by perforin and granzyme B in renal allografts. Hum Immunol 2006 Oct;67(10):777–786.
   PubMed Web of Science ®Google Scholar
• Halloran P. Immunosuppressive drugs for kidney transplantation. N Engl J Med 2004 Dec;351(26):2715–2729.
   PubMed Web of Science ®Google Scholar
• Dörje C, Midtevedt K, Holdaas H, et al. Early versus late acute antibody-mediated rejection in renal transplant recipients. Transplantation 2013 Jul;19(3):315–322.
   Google Scholar
• Haas M. An updated Banff schema for diagnosis of antibody-mediated rejection in renal allografts. Curr Opin Organ Transplant 2014 Jun;19(3):315–322.
   PubMed Web of Science ®Google Scholar
• Solez K, Covin R, Racusen I, et al. Banff 07 classification of renal allograft pathology: updates and future directions. Am J Transplant 2008 Apr;8(4):753–760.
   PubMed Web of Science ®Google Scholar
• Sis B, Campbell P, Mueller T, et al. Transplant glomerulopathy, late antibody-mediated rejection and the ABCD tetrad in kidney allograft biopsies for cause. Am J Transplant 2007;7:1743–1752.
   PubMed Web of Science ®Google Scholar
• Schinstock C, Stegall M, Cosio F. New insights regarding chronic antibody-mediated rejection and its progression to transplant glomerulopathy. Curr Opin Nephrol Hypertens 2014;23(6):611–618.
   PubMed Web of Science ®Google Scholar
• Racusen L, Haas M. Antibody-mediated rejection in renal allografts: lessons from pathology. Clin J Am Soc Nephrol 2006 Jan;1:625–630.
   Web of Science ®Google Scholar
• Tratanon O, Poggio E, Fairchild R. Molecular monitoring of alloimmune-mediated injury in kidney transplant patients. 2014 Nov;23(6):625–630.
   Google Scholar
• Heidt S, Eikmans M, Roelen D, Claas F. Novel strategies for immunological monitoring of kidney transplant recipients: from microRNA to alloantibodies. Clin Transpl 2013:257–267.
   PubMedGoogle Scholar
• Perkins D, Verma M, Park K. Advances of genomic science and systems biology in renal transplantation: a review. Semin Immunopathol 2011 Mar;33(2):211–218.
   PubMed Web of Science ®Google Scholar
• Mas V, Mueller T, Archer K, Maluf D. Identifying biomarkers as diagnostic tools in kidney transplantation. Expert Rev Mol Diagn 2011 Mar;11(2):183–196.
   PubMed Web of Science ®Google Scholar
• Mueller T, Einecke G, Reeve J, et al. Microarray analysis of rejection in human kidney transplants using pathogenesis-based transcript sets. Am J Transplant 2007 Dec;7(12):2712–2722.
   PubMed Web of Science ®Google Scholar
• Hartono C, Muthukumar T, Suthanthiran M. Noninvasive diagnosis of acute rejection of renal allografts. Curr Opin Organ Transplant 2010 Feb;15(1):35–41.
   PubMed Web of Science ®Google Scholar
• Reeve J, Einecke G, Mengel M, et al. Diagnosing rejection in renal transplants: a comparison of molecular- and histopathology-based approaches. Am J Transplan 2009 Aug;9(8):1802–1810.
   PubMed Web of Science ®Google Scholar
• Sigdel T, Salomonis N, Nicora C, et al. The identification of novel potential injury mechanisms and candidate biomarkers in renal allograft rejection by quantitative proteomics. Mol Cell Proteomics 2014 Feb;13(2):621–631.
   PubMed Web of Science ®Google Scholar
• Lo D, Kaplan B, Kirk, AD. Biomarkers for kidney transplant rejection. Nat Rev Nephrol 2014 April;10(4):215–225.
   PubMed Web of Science ®Google Scholar
• Suthanthiran M, Swhwartz J, Ding R, et al. Clinical Trials in Organ Transplantation 04 (CTOT-04) study investigators. Urinary-cell mRNA profile and acute cellular rejection in kidney allografts. N Engl J Med 2013 Jul;369(1):20–31.
   PubMed Web of Science ®Google Scholar
• Lee J, Muthukumar T, Dadhania D, et al. Urinary cell mRNA profiles predictive of human kidney allograft status. Immunol Rev 2014 Mar;258(1):218–240.
   PubMed Web of Science ®Google Scholar
• Sigdel T, Ng Y, Lee S, et al. Perturbations in the urinary exosome in transplant rejection. Front Med. 2015 Jan;5:1–57.
   PubMedGoogle Scholar
• Mas V, Dumur C, Scian M, et al. MicroRNAs as biomarkers in solid organ transplantation. Am J Transplant 2013 Jan;13(1):11–19.
   PubMed Web of Science ®Google Scholar
• Mehrotra A, Leventhal J, Purroy C, Cravedi P. Monitoring T cell alloreactivity. Transplant Rev 2015 Apr;29(2):53–59.
   Web of Science ®Google Scholar
• Cucchiari D, Podestá M, Ponticelli C. The critical role of innate immunity in kidney transplantation. Nephron 2016;132(3):227–237.
   PubMed Web of Science ®Google Scholar
• Hricik D. Transplant immunology and immunosupression: core curriculum 2015. Am J Kidney Dis 2015 Jun;65(5):956–966.
   PubMed Web of Science ®Google Scholar
• Filippone E, Farber J. Humoral immune response and allograft function in kidney transplantation. Am J Kidney Dis 2015 Aug;66(2):337–347.
   PubMed Web of Science ®Google Scholar
• Salvadé I, Aubert V, Venetz J, et al. Clinically relevant threshold of preformed donor-specific anti-HLA antibodies in kidney transplantation. Hum Immunol 2016 Apr;16:S0198–S8859.
   Google Scholar
• Malheiro J, Tafulo S, Dias L, et al. Analysis of preformed donor-specific anti-HLA antibodies characteristics for prediction of antibody-mediated rejection in kidney transplantation. Transpl Imunol 2015 Mar;32(2):66–71.
   PubMed Web of Science ®Google Scholar
• Gebel H, Bray R, Nickerson P. Pre-transplant assessment of donor-reactive, HLA-specific antibodies in renal transplantation: contraindication vs. risk. Am J Transplant 2003 Dec;3(12):1488–1500.
   PubMed Web of Science ®Google Scholar
• Vicenti F, Cohen S, Appel G. Novel B cell therapeutic targets in transplantation and imune-mediated glomerular diseases. Clin J Am Soc Nephrol 2010 Jan;5(1):142–151.
   PubMed Web of Science ®Google Scholar
• Borel J, Feurer C, Gubler H, Stahelin H. Biological effects of cyclosporin A: a new antilymphocytic agent. Agents Actions 1976;6:468–475.
   PubMedGoogle Scholar
• Wiseman A. Immunosuppressive medications. Clin J Am Soc Nephrol 2016 Feb;11(2):332–343.
   PubMed Web of Science ®Google Scholar
• Schreiber S, Crabtree G. The mechanisms of action of cyclosporin A and FK506. Immunol Today 1992;13:136.
   PubMedGoogle Scholar
• Morris P. Some experimental and clinical studies of cyclosporin A in renal transplantation. Transplant Proc. 1982 Sep;14(3):525–528.
   PubMed Web of Science ®Google Scholar
• Kahan B, van Buren C, Flechner S, et al. Clinical and experimental studies with cyclosporine in renal transplantation. Surgery 1985 Feb;97(2):125–140.
   PubMed Web of Science ®Google Scholar
• Cyclosporin in cadaveric renal transplantation: one-year follow-up of a multicentre trial. Lancet 1983 Oct 29;2(8357):986–989.
   Web of Science ®Google Scholar
• Ferguson R, Rynasiewics J, Sutherland D, et al. Cyclosporin A in renal transplantation: a prospective randomized trial. Surgery 1982 Aug;92(2):175–182.
   PubMed Web of Science ®Google Scholar
• Molnar A, Fergusson D, Tsampalieros A, et al. Generic immunosuppression in solid organ transplantation: systematic review and meta-analysis. Brit Med J 2015 Jun 22;350:h3163.
   PubMed Web of Science ®Google Scholar
• Cohen D, Loertscher R, Rubin M, et al. Cyclosporine: a new immunosuppressive agent for organ transplantation. Ann Intern Med 1984 Nov;101(5):667–682.
   PubMed Web of Science ®Google Scholar
• Gill J, Tonelli M, Mix C, et al. The effect of maintenance immunosuppression medication on the change in kidney allograft function. Kidney Int. 2004 Feb;65(2):692–699.
   PubMed Web of Science ®Google Scholar
• First M. Tacrolimus-based immunosuppression. J Nephrol 2004 Nov–Dec;17(Suppl 8):25–31.
   Google Scholar
• Webster A, Woodroffe R, Taylor R, et al. Tacrolimus versus cyclosporin as primary immunosuppression for kidney transplant recipients. Cochrane Database Syst Rev 2005 Oct;19(4):CD003961.
   Google Scholar
• Webster A, Woodroof R, Taylor R, et al. Tacrolimus versus ciclosporin as primary immunosuppression for kidney transplant recipients: meta-analysis and meta-regression of randomised trial data. Brit Med J 2005 Oct 8;331(7520):810.
   PubMed Web of Science ®Google Scholar
• Kälble T, Lucan M, Nicita G, et al. European Association of Urology. EAU guidelines on renal transplantation. Eur Urol 2005 Feb;47(2):156–166.
   PubMed Web of Science ®Google Scholar
• Helal I, Chan L. Steroid and calcineurin inhibitor-sparing protocols in kidney transplantation. Transplant Proc 2011 Mar;43(2):472–477.
   PubMed Web of Science ®Google Scholar
• Knight S, Russel N, Barcena L, Morris P. Mycophenolate mofetil decreases acute rejection and may improve graft survival in renal transplant recipients when compared with azathioprine: a systematic review. Transplantation 2009 Mar;87(6):785–794.
   PubMed Web of Science ®Google Scholar
• Clayton P, McDonald S, Chapman J, Chadban S. Mycophenolate versus azathioprine for kidney transplantation: a 15-year follow-up of a randomized trial. Transplantation 2012 Jul;94(2):152–158.
   PubMed Web of Science ®Google Scholar
• Woodroffe R, Yao G, Meads C, et al. Clinical and cost-effectiveness of newer immunosuppressive regimens in renal transplantation: a systematic review and modelling study. Health Technol Assess 2005 May;9(21):1–179.
   PubMed Web of Science ®Google Scholar
• Shihab F, Christians U, Smith L, et al. Focus on mTOR inhibitors and tacrolimus in renal transplantation: pharmacokinetics, exposure-response relationships, and clinical outcomes. Transpl Immunol 2014 Jun;31(1):22–32.
   PubMed Web of Science ®Google Scholar
• Hernández D, Martinez D, Gutiérrez E, et al. Clinical evidence on the use of anti-mTOR drugs in renal transplantation. Nefrologia 2011;31(1):27–34.
   PubMed Web of Science ®Google Scholar
• Helal I, Chan L. Steroid and calcineurin inhibitor-sparing protocols in kidney transplantation. Transplant Proc 2011 Mar;43(2):472–477.
   PubMed Web of Science ®Google Scholar
• Meier-Kriesche H, Schold J, Srinivas T, Kaplan B. Lack of improvement in renal allograft survival despite a marked decrease in acute rejection rates over the most recent era. Am J Transplant 2004 Mar;4(3):378–383.
   PubMed Web of Science ®Google Scholar
• Karam S, Wali R. Current state of immunosuppression: past, present, and future. Crit Rev Eukaryot Gene Expr 2015;25(2):113–134.
   PubMed Web of Science ®Google Scholar
• Lamb K, Lodhi S, Meier-Kriesche H. Longterm renal allograft survival in the United States: a critical reappraisal. Am J Transplant 2011;11:450–462.
   PubMed Web of Science ®Google Scholar
• Brent L. The 50th anniversary of the discovery of immunologic tolerance. N Engl J Med 2003 Oct 2;349(14):1381–1383.
   PubMed Web of Science ®Google Scholar
• Billingham R, Brent L, Medawar P. Actively acquired tolerance of foreign cells. Nature 1953 Oct 3;172(4379):603–606.
   PubMed Web of Science ®Google Scholar
• Salama A, Remuzzi G, Harmon W, Sayegh M. Challenges to achieving clinical transplantation tolerance. J Clin Invest 2001 Oct;108(7):943–948.
   PubMed Web of Science ®Google Scholar
• Ansari M, Sayegh M. Clinical transplantation tolerance: the promise and challenges. Kidney Int 2004 May;65(5):1560–1563.
   PubMed Web of Science ®Google Scholar
• Sayegh MH, Perico N, Remuzzi G. Transplantation tolerance. A complex scenario awaiting clinical applicability. 2005;146:95–104. Review.
   Google Scholar
• Azzi J, Sayegh MH. Clinical transplantation tolerance: a myth no more, but. Am J Kidney Dis 2009 Dec;54(6):1005–1011.
   PubMed Web of Science ®Google Scholar
• Bemark M. Translating transitions – how to decipher peripheral human B cell development. J Biomed Res 2015 Jul;29(4):264–284.
   PubMed Web of Science ®Google Scholar
• Dummer C, Carpio V, Gonçalves L, et al. FOXP3+ regulatory T cells: from suppression of rejection to induction of renal allograft tolerance. Transpl Immunol 2012 Jan;26(1):1–10.
   PubMed Web of Science ®Google Scholar
• Siemionow M, Unal S. Strategies for tolerance induction in nonhuman primates. Ann Plast Surg 2005 Nov;55(5):545–553.
   PubMed Web of Science ®Google Scholar
• Hamawy M, Knechtle S. Strategies for tolerance induction in nonhuman primates. Curr Opin Immunol 1998 Oct;10(5):513–517.
   PubMed Web of Science ®Google Scholar
• Montgomery SSP, Hale DA, Hirshberg B, Harlan DM, Kirk AD, et al. Preclinical evaluation of tolerance induction protocols and islet transplantation in non-human primates. Immunol Rev 2001;183:214–222. Review.
   PubMed Web of Science ®Google Scholar
• Montgomery S, et al. Combination induction therapy with monoclonal antibodies specific for CD80, CD86, and CD154 in nonhuman primate renal transplantation. Transplantation 2002;74: 1365–1369.
   PubMed Web of Science ®Google Scholar
• Sharabi Y, Sachs D. Mixed chimerism and permanent specific transplantation tolerance induced by a nonlethal preparative regimen. J Exp Med 1989;169:493–502.
   PubMed Web of Science ®Google Scholar
• Kawai T, Sachs D. Tolerance induction: hematopoietic chimerism. Curr Opin Organ Transplant 2013 Aug;18(4):402–407.
   PubMed Web of Science ®Google Scholar
• Cosimi A, Sachs D, Sykes M, Kawai T. Clinical strategy for induction of transplantation tolerance through mixed chimerism. Clin Transplan 2013:127–134.
   PubMedGoogle Scholar
• Murakami T, Cosimi A, Kawai T. Mixed chimerism to induce tolerance: lessons learned from nonhuman primates. Transplant Rev 2009 Jan;23(1):19–24.
   Google Scholar
• Kawai T, Cosimi A, Sachs D. Preclinical and clinical studies on the induction of renal allograft tolerance through transient mixed chimerism. Curr Opin Organ Transplant 2011 Aug;16(4):366–371.
   PubMed Web of Science ®Google Scholar
• Tomita Y, Khan A, Sykes M. Role of intrathymic clonal deletion and peripheral anergy in transplantation tolerance induced by bone marrow transplantation in mice conditioned with a nonmyeloablative regimen. J Immunol 1994;153:1087–1098.
   PubMed Web of Science ®Google Scholar
• Kawai T, Leventhal K, Madsen J, et al. Tolerance: one transplant for life. Transplantation 2014 Jul 27;98(2):117–121.
   PubMed Web of Science ®Google Scholar
• Kawai T, Cosimi A, Spitzer T, et al. HLA-mismatched renal transplantation without maintenance immunosuppression. N Engl J Med. 2008 Jan 24;358(4):353–361.
   Web of Science ®Google Scholar
• Sachs D.Transplant tolerance: bench to bedside – 26th Annual Samuel Jason Mixter Lecture. Arch Surg 2011 May;146(5):501–505.
   PubMedGoogle Scholar
• Starzl T. Clinical and basic scientific implications of cell migration and microchimerism after organ transplantation. Artif Organs 1997 Nov;21(11):1154–1155.
   PubMed Web of Science ®Google Scholar
• Starzl T, Demetris A. Transplantation tolerance, microchimerism, and the two-way paradigm. Theor Med Bioeth 1998 Sep;19(5):441–455.
   PubMed Web of Science ®Google Scholar
• Starzl T. Chimerism and tolerance in transplantation. Proc Natl Acad Sci USA 2004 Aug;101(Suppl 2):15607–15614.
   Google Scholar
• Leventhal J, Abecassis M, Miller J, et al. Chimerism and tolerance without GVHD or engraftment syndrome in HLA-mismatched combined kidney and hematopoietic stem cell transplantation. Sci Transl Med 2012;4:124–128.
   Web of Science ®Google Scholar
• Scandling J, Busque S, Shizuru J, et al. Induced immune tolerance for kidney transplantation. N Engl J Med. 2011 Oct;365(14):1359–1360.
   PubMed Web of Science ®Google Scholar
• Scandling J, Busque S, Shizuru J, et al. Chimerism, graft survival, and withdrawal of immunosuppressive drugs in HLA-matched and mismatched patients after living donor kidney and hematopoietic cell transplantation. Am J Transplant 2015 Mar;15(3):695–704.
   PubMed Web of Science ®Google Scholar
• Kawai T, Sachs D, Sprangers B, et al. Long-term results in recipients of combined HLA-mismatched kidney and bone marrow transplantation without maintenance immunosuppression. Am J Transplant 2014 Jul;14(7):1599–1611.
   PubMed Web of Science ®Google Scholar
• Leventhal J, Abecassis M, Miller J, et al. Tolerance induction in HLA disparate living donor kidney transplantation by donor stem cell infusion: durable chimerism predicts outcome. Transplantation 2013 Jan 15;95(1):169–176.
   PubMed Web of Science ®Google Scholar
• Sakaguchi S, Wing K, Miyara M. Regulatory T cells – a brief history and perspective. Eur J Immunol 2007 Nov;37(Suppl 1):S116–S123.
   PubMed Web of Science ®Google Scholar
• Barber W, Mankin J, Laskow D. Long-term results of a controlled prospective study with transfusion of donor-specific bone marrow in 57 cadaveric renal allograft recipients. Transplantation 1991 Jan;51(1):70–75.
   PubMed Web of Science ®Google Scholar
• Orlando G, Hematti P, Stratta R, et al. Clinical operational tolerance after renal transplantation: current status and future challenges. Ann Surg 2010 Dec;252(6):915–928.
   PubMed Web of Science ®Google Scholar
• Sachs D, Kawai T, Skyes M. Induction of tolerance through mixed chimerism. Cold Spring Harb Perspect Med 2014 Jan;4(1):a015529.
   PubMed Web of Science ®Google Scholar
• Fändrich F. Tolerance in clinical transplantation: progress, challenge or just a dream? Langencecks Arch Surg 2011 Apr;396(4):475–487.
   PubMed Web of Science ®Google Scholar
• Elias N, Cosimi A, Kawai T. Clinical trials for induction of renal allograft tolerance. Curr Opin Organ Transplant 2015 Aug;20(4):406–411.
   PubMed Web of Science ®Google Scholar
• Shrestha B, Haylor J, Raftery A. Historical perspectives in kidney transplantation: an updated review. Prog Transplant 2015 Mar;25(1):64–69.
   PubMed Web of Science ®Google Scholar
• Marfo K, Lu A, Ling M, et al. Desensitization protocols and their outcome. Clin J Am Soc Nephrol 2011 Apr;6(4):922–936.
   PubMed Web of Science ®Google Scholar
• Land W. Chronic allograft dysfunction: a model disorder of innate immunity. Biomed J. 2013 Mar;258(1):145–149.
   Google Scholar